Journal List > Perinatology > v.27(3) > 1071329

Cho, Koo, Chung, Bae, and Choi: A Case of Ibuprofen Induced Transient Platelet Dysfunction in Preterm Infant

Abstract

Patent ductus arteriosus (PDA) in preterm infant is a common cardiovascular disease that result in hemodynamic disturbance. Ibuprofen treatment is currently being used for PDA closure either intravenously or enterally, and it has been demonstrated that ibuprofen have the same efficacy as indomethacin treatment for PDA closure. We encountered a case of severe gastrointestinal bleeding occurred in the administration of oral ibuprofen for the treatment of PDA in preterm infant. It was diagnosed with a transient platelet dysfunction due to oral ibuprofen treatment by analyzing through the Platelet function analysis (PFA) test. We present this case to emphasize the importance of close follow-up of preterm infant during oral ibuprofen treatment even though good enteral feeding.

References

1. Tatli MM, Kumral A, Dunman N, Demir K, Gurcu O, Ozkan H. Spontaneous intestinal perforation after oral ibuprofen treatment of patent ductus arteriosus in two very-low-birthweight infants. Acta Paediatr. 2004; 93:999–1001.
crossref
2. Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, Degroote K. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Eng J Med. 2000; 343:674–681.
crossref
3. Erdeve O, Yurttutan S, Altug N, Ozdemir R, Gokmen T, Dilmen U, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2012; 97:F279–F283.
crossref
4. Supapannachart S, Limrungsikul A, Khowsathit P. Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital. J Med Assoc Thai. 2002; 85:Suppl 4. S1252–S1258.
5. Sarici SU, Dabak O, Erdinc K, Okutan V, Lenk MK. An unreported complication of intravenously administered ibuprofen: gastrointestinal bleeding. Eur Rev Med Pharmacol Sci. 2012; 16:325–327.
6. Sangtawesin V, Sangtawesin C, Raksasinborisut C, Sathirakul K, Kanjanapattanakul W, Khorana M, et al. Oral ibuprofen prophylaxis for symptomatic patent ductus arteriosus of prematurity. J Med Assoc Thai. 2006; 89:314–321.
7. Lee JH. Strategy of diagnosis and treatment for hemodynamically significant patent ductus arteriosus in preterm infants. Korean J Perinatol. 2013; 24:72–81.
8. Varvarigou A, Bardin CL, Beharry K, Chemtob S, Papageorgiou A, Aranda JV, et al. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA. 1996; 275:539–544.
crossref
9. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994; 343:769–772.
crossref
10. Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns. Pediatrics. 2003; 112:e354.
11. Harrison P. Platelet function analysis. Blood rev. 2005; 19:111–123.
crossref
12. Israels SJ, Cheang T, McMillan-Ward EM, Cheang M. Evaluation of primary hemostasis in neonates with a new in vitro platelet function analyzer. J Pediatr. 2001; 138:116–119.
crossref
13. Cariappa R, Wilhite TR, Parvin CA, Luchtman-Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol. 2003; 25:474–479.
crossref
TOOLS
Similar articles